Kiromic Biopharma, Inc. financial data

Location
Houston, TX
Fiscal year end
31 December
Latest financial report
10-K - Q4 2024 - 14 Feb 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 25% % 3.8%
Debt-to-equity -228% % 21%
Return On Equity 314% % 5.1%
Return On Assets -245% % -56%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,533,272 shares
Common Stock, Shares, Outstanding 1,533,272 shares 22%
Entity Public Float $3,377,900 USD 6.4%
Common Stock, Value, Issued $2,000 USD 100%
Weighted Average Number of Shares Outstanding, Basic 1,304,548 shares 49%
Weighted Average Number of Shares Outstanding, Diluted 1,304,548 shares 49%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $6,854,000 USD -1.4%
General and Administrative Expense $8,853,000 USD -14%
Operating Income (Loss) $23,774,000 USD -19%
Nonoperating Income (Expense) $832,000 USD -161%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $26,898,000 USD -28%
Earnings Per Share, Basic -7 USD/shares 87%
Earnings Per Share, Diluted -7 USD/shares 87%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,137,000 USD -65%
Assets, Current $3,301,000 USD -25%
Property, Plant and Equipment, Net $4,310,000 USD -30%
Operating Lease, Right-of-Use Asset $913,000 USD -41%
Other Assets, Noncurrent $21,000 USD 0%
Assets $8,545,000 USD -30%
Accounts Payable, Current $2,676,000 USD 25%
Employee-related Liabilities, Current $1,780,000 USD 106%
Liabilities, Current $20,904,000 USD 2.6%
Operating Lease, Liability, Noncurrent $228,000 USD -75%
Liabilities $21,132,000 USD -0.74%
Retained Earnings (Accumulated Deficit) $149,795,000 USD -22%
Stockholders' Equity Attributable to Parent $12,587,000 USD -38%
Liabilities and Equity $8,545,000 USD -30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,699,000 USD -38%
Net Cash Provided by (Used in) Financing Activities $6,192,000 USD 12%
Net Cash Provided by (Used in) Investing Activities $21,000 USD
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 1,533,272 shares 22%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $472,000 USD -67%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,795,000 USD -44%
Interest Paid, Excluding Capitalized Interest, Operating Activities $5,000 USD -62%
Deferred Tax Assets, Valuation Allowance $28,526 USD 27%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross $28,718 USD 26%
Operating Lease, Liability $913,000 USD -41%
Depreciation $2,234,000 USD 0.58%
Payments to Acquire Property, Plant, and Equipment $21,000 USD
Lessee, Operating Lease, Liability, to be Paid $968,000 USD -43%
Property, Plant and Equipment, Gross $11,465,000 USD 3.3%
Operating Lease, Liability, Current $685,000 USD 8.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $243,000 USD -66%
Lessee, Operating Lease, Liability, to be Paid, Year One $725,000 USD 1%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $55,000 USD -61%
Deferred Tax Assets, Operating Loss Carryforwards $19,519 USD 21%
Preferred Stock, Shares Issued 36,835 shares 163%
Preferred Stock, Shares Authorized 60,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $137,206,000 USD 21%
Preferred Stock, Shares Outstanding 36,835 shares 163%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%